Cabozantinib in medullary thyroid carcinoma: time to focus the spotlight on this rare disease
- PMID: 21606409
- DOI: 10.1200/JCO.2010.34.0505
Cabozantinib in medullary thyroid carcinoma: time to focus the spotlight on this rare disease
Comment on
-
Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer.J Clin Oncol. 2011 Jul 1;29(19):2660-6. doi: 10.1200/JCO.2010.32.4145. Epub 2011 May 23. J Clin Oncol. 2011. PMID: 21606412 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources
Other Literature Sources
